# US 8,772,042 B2 · Biomarkers for diagnosing alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,042 B2
- Document ID: US8772042B2
- Status: Granted
- Kind: B2
- Application number: 13/099,110
- Filed: 2011-05-02
- Published: 2012-01-19
- Granted: 2014-07-08
- Earliest claimed: 2002-08-23
- Assignees: Bayer Intellectual Property GmbH
- Applicants: Özkan Yalkinoglu; Gerhard König; Denis Francois Hochstrasser; Jean-Charles Sanchez; Odile Carrette
- Inventors: Özkan Yalkinoglu; Gerhard König; Denis Francois Hochstrasser; Jean-Charles Sanchez; Odile Carrette
- Web page: https://patentgrep.com/patent/US8772042B2

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 14/805: Haemoglobins; Myoglobins
- C07K 14/8139: {Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin}
- G01N 2800/2821: Alzheimer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.

## Claims

### Claim 1

A method for assessing the state of Alzheimer's disease in a subject, wherein the method comprises detecting in a sample from the subject at least five distinct polypeptides meeting the following criteria:
a first polypeptide having the amino acid sequence of SEQ ID NO: 17;
a second polypeptide having the amino acid sequence of SEQ ID NO: 1 or 2;
a third polypeptide having the amino acid sequence of SEQ ID NO: 3;
a fourth polypeptide having the amino acid sequence of SEQ ID NO: 4, 5, or 6; and
a fifth polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 7 to SEQ ID NO: 16.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further comprises contacting the sample with an antibody that specifically binds to one of the at least five polypeptides.

### Claim 3 (depends on 1)

The method of claim 1, wherein one or more of the at least five polypeptides is detected by SELDI-TOF MS.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method is performed on at least two samples from the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sample is CSF, blood, serum, plasma, urine, seminal plasma, nipple fluid, or cell extract.